Gencurix

A new paradigm in molecular diagnostics through advanced liquid biopsy

Seoul, South Korea · $52.1M raised

Headquarters
Seoul
Employees
51–200
Business Model
B2B
Total Funding
$52.1M
Last Round
$24.0M Series AMar 2026
Rounds
3

About

Gencurix (젠큐릭스) is a South Korean molecular diagnostics biotech company specializing in liquid biopsy and digital PCR-based cancer diagnostics. The company was the first Asian company to develop a prognostic diagnostic test for breast cancer and offers a portfolio of CE-IVD certified products including the Droplex cancer gene mutation detection kit, the GenesWell BCT breast cancer test, and the eDX early cancer detection system. In 2025, Gencurix signed a global supply and co-marketing agreement with Bio-Rad Laboratories — the world's largest digital PCR diagnostics company — to distribute its Droplex kits across Europe, marking a major commercial milestone for the company.

Summary

Gencurix is a Biotech company based in Seoul, South Korea. It has raised $52.1M in total across 3 rounds, most recently a $24.0M Series A round in Mar 2026. Investors include Korea Investment Partners and Union Ventures.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AMar 2026
$24.0M

Sign up to see all 3 rounds

Seed through Series A — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Gencurix on Indexed.vc
<a href="https://indexed.vc/companies/gencurix"><img src="https://indexed.vc/api/badge/company/gencurix" alt="Gencurix on Indexed.vc" width="260" height="76" /></a>